Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
PR Newswire•10/08/2026•07:30 ET
0
Whiz Insights
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy
Get started
Create a free account to read the full story.